Spruce Biosciences, Inc. Financing Cash Flow
Spruce Biosciences, Inc. (SPRB) reported Financing Cash Flow of $78.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $64.47M.
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $13.92M.
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $44.69M.
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$402.00K.
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $43.48M.
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$1.62M, a 103.30% decline from fiscal 2023.
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $49.14M.
- Spruce Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$241.00K, a 137.48% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $64.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $78.39M 10-Q · filed 2026-08-12 | $123.08M derived: sum of 3 quarters · filed 2026-08-12 | $122.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $13.92M 10-Q · filed 2026-05-13 | $58.61M derived: sum of 2 quarters · filed 2026-05-13 | $58.21M derived: sum of 3 quarters · filed 2026-05-13 | $57.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $44.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $44.29M derived: sum of 2 quarters · filed 2026-03-09 | $43.89M derived: sum of 3 quarters · filed 2026-08-12 | $43.48M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$802.00K derived: sum of 2 quarters · filed 2026-08-12 | -$1.21M 10-Q · filed 2025-11-10 | -$1.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$811.00K 10-Q · filed 2026-08-12 | -$1.44M derived: sum of 3 quarters · filed 2026-08-12 | -$1.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$411.00K 10-Q · filed 2026-05-13 | -$1.04M derived: sum of 2 quarters · filed 2026-05-13 | -$1.44M derived: sum of 3 quarters · filed 2026-05-13 | -$1.81M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$625.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.03M derived: sum of 2 quarters · filed 2026-03-09 | -$1.40M derived: sum of 3 quarters · filed 2026-03-09 | -$1.62M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$405.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$770.00K derived: sum of 2 quarters · filed 2025-11-10 | -$997.00K 10-Q · filed 2025-11-10 | -$1.55M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$365.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$592.00K 10-Q · filed 2025-08-14 | -$1.14M derived: sum of 3 quarters · filed 2025-08-14 | -$1.55M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$227.00K 10-Q · filed 2025-05-06 | -$779.00K derived: sum of 2 quarters · filed 2025-05-06 | -$1.18M derived: sum of 3 quarters · filed 2025-05-06 | -$1.62M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$552.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$957.00K derived: sum of 2 quarters · filed 2025-04-15 | -$1.39M derived: sum of 3 quarters · filed 2025-04-15 | $49.14M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$405.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$837.00K derived: sum of 2 quarters · filed 2024-11-12 | $49.69M 10-Q · filed 2024-11-12 | $49.73M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $50.10M 10-Q · filed 2024-08-12 | $50.13M derived: sum of 3 quarters · filed 2024-08-12 | $50.04M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $50.53M 10-Q · filed 2024-05-13 | $50.56M derived: sum of 2 quarters · filed 2024-05-13 | $50.48M derived: sum of 3 quarters · filed 2024-05-13 | $50.38M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$54.00K derived: sum of 2 quarters · filed 2024-03-18 | -$153.00K derived: sum of 3 quarters · filed 2024-03-18 | -$241.00K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$189.00K derived: sum of 2 quarters · filed 2023-11-13 | -$277.00K 10-Q · filed 2023-11-13 | -$110.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$187.00K 10-Q · filed 2023-08-14 | -$20.00K derived: sum of 3 quarters · filed 2023-08-14 | -$3.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$88.00K 10-Q · filed 2023-05-15 | $79.00K derived: sum of 2 quarters · filed 2023-05-15 | $96.00K derived: sum of 3 quarters · filed 2023-05-15 | $272.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $184.00K derived: sum of 2 quarters · filed 2023-03-16 | $360.00K derived: sum of 3 quarters · filed 2023-03-16 | $643.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $193.00K derived: sum of 2 quarters · filed 2022-11-10 | $476.00K 10-Q · filed 2022-11-10 | $94.76M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $459.00K 10-Q · filed 2022-08-10 | $94.74M derived: sum of 3 quarters · filed 2022-08-10 | $137.94M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $283.00K 10-Q · filed 2022-05-11 | $94.56M derived: sum of 2 quarters · filed 2022-05-11 | $137.76M derived: sum of 3 quarters · filed 2022-05-11 | $137.66M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $94.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $137.48M derived: sum of 2 quarters · filed 2022-03-14 | $137.38M derived: sum of 3 quarters · filed 2022-03-14 | $181.03M 10-K · filed 2022-03-14 |
| 2020-09-30 | $43.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $43.10M derived: sum of 2 quarters · filed 2021-11-15 | $86.75M 10-Q · filed 2021-11-15 | $88.75M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $43.56M 10-Q · filed 2021-08-10 | $45.56M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | $43.66M 10-Q · filed 2021-05-12 | $45.66M derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $12.43M 10-K · filed 2021-03-22 | ||
| 2019-09-30 | $10.43M 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |